advanced heart failure News
-
Groundbreaking Use of Radar-Equipped Vests in a Hospital Promises to Improve the Care of Heart Failure Patients
Dr. Dan Bensimhon tends to see things differently. At a conference, the director of the Cone Health Advanced Heart Failure Clinic noticed a small vest that uses military technology to measure fluid in the lungs of patients. The company saw the vest as a way for people with heart failure to catch fluid buildup at home before it became a problem. Bensimhon saw the vest as an opportunity to ...
-
Genomic Advances in Heart Failure
Heart failure is a significant global health issue. More than half of the people who develop heart failure die within 5 years. Current treatments do not help the largest group of these patients – those with heart failure with preserved ejection fraction (HFpEF) – and have limited effectiveness for those with reduced injection fraction (HFrEF). HFpEF has been called the greatest unmet ...
-
Cone Health using radar technology to better treat heart failure
Congestive heart failure is one of the most common reasons elderly people end up in the hospital. When this happens fluid builds up in the lungs and patients have trouble breathing. Cone Health is the first in the country to use a new technology to measure the amount of fluid in the lungs in the inpatient hospital setting. “Now we have a device that lets us know in 90 seconds whether there ...
-
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD). These data were presented at the International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and ...
-
Endotronix Hires Industry Veteran Jim Yearick as Senior Vice President of Sales and Marketing
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President of Sales and Marketing. Mr. Yearick will oversee Endotronix’s worldwide sales and marketing efforts for the Cordella™ Heart Failure System (Cordella ...
-
Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeart™
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention ...
-
V-Wave’s Ventura interatrial shunt: one year follow-up from relieve-HF Roll-in arm shows improved left and right ventricular function in patients with advanced heart failure
V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy. ...
By V-Wave Ltd.
-
Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function ...
-
V-Wave completes financing of $98m from syndicate of leading global healthcare investors
Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C extension totaling $98M. The financing ...
By V-Wave Ltd.
-
V-Wave completes financing of up to $98m from syndicate of leading Global Healthcare Investors
V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has closed a Series C extension of up to $98M. The financing assures capital to complete clinical trials for the Ventura® Interatrial Shunt for the ...
By V-Wave Ltd.
-
Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor1, shifting ...
-
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using the Revivent TC TransCatheter Ventricular ...
-
V-Wave receives second FDA breakthrough device designation: interatrial shunt for pulmonary arterial hypertension
V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union. “More than 26 million people suffer from chronic heart failure worldwide, and HF remains a leading driver of ...
By V-Wave Ltd.
-
V-Wave Receives CE Mark for the Ventura Interatrial Shunt System
V-Wave Ltd., a privately held medical device company developing novel implantable devices for the treatment of Heart Failure (HF), today announced that its Ventura™ Interatrial Shunt System received CE Mark and is now approved to be marketed for use in the European Union. “More than 26 million people suffer from chronic heart failure worldwide, and HF remains ...
By V-Wave Ltd.
-
Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
-
William T. Abraham, MD, Joins V-Wave as Chief Medical Officer
V-Wave Ltd., an early stage medtech company developing an implantable interatrial shunt device for treating advanced heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that renowned heart failure cardiologist, William T. Abraham, MD, is joining V-Wave as Chief Medical Officer. Dr. Abraham makes this move to V-Wave after more than 16 years as Director of the Division of ...
By V-Wave Ltd.
-
Endotronix Enrolls First Patient in SIRONA II CE Mark Trial
Endotronix Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced enrollment of the first patient in its prospective, multi-center, SIRONA II trial, in Europe. The 60-patient study will evaluate safety and efficacy of the Cordella™ Pulmonary Artery Pressure Sensor System (Cordella Sensor) in support of its CE Mark ...
-
Berlin Heart Enrolls First Patients in Clinical Study to Investigate Innovative Mobilization Option for Children Waiting for a Heart Transplantation
Berlin Heart is pleased to announce that the first patients are enrolled in the "E-MOTION" study: “The use of the EXCOR® Active driving unit for MObilizaTION of pediatric patients with Ventricular Assist Device support”. This observational, international, multi-center study investigates the improved mobility, patient outcome and the impact of the mobile driving concept ...
-
AdjuCor receives further funding for its innovative heart assist device which avoids blood-contact and supports patients with heart failure.
MUNICH, Germany – August 26th, 2019: After reaching a key milestone towards clinical application with a successful 60 day in-vivo study, AdjuCor announces the closure of a new financing round with Hirschvogel Vermögensverwaltung GmbH, a Bavarian Investor who intends to further expand its activity into the medical device arena. Hirschvogel Vermögensverwaltung GmbH announces its ...
By AdjuCor GmbH
-
CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies
Mr. Bruno Le Maire, Economy and Finance Minister and Mr. Cédric O, Secretary of State for Digital Transition and Electronic Communications, announced the selection of CorWave to join the French Tech 120 index, designed for the best French startups with the capacity to become global leaders. CorWave is one of five medtech startups selected in the French Tech 120 index. The French ...
By CorWave
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you